Advertisement

High-frequency aflibercept injections in persistent neovascular age-related macular degeneration

  • Dan Călugăru
  • Mihai Călugăru
Letter to the Editor

Dear Editor:

We would like to address several challenges that have arisen from the study by Muftuoglu et al. [1] which are specifically summarized below.

Relevant data are missing from the study (Table 1).
Table 1

Missing data from the article by Muftuoglu et al. [1]

Variables

 

The baseline characteristics of patients at the time of switching from Q4W bevacizumab/ranibizumab injections to Q8W aflibercept injections

 

The washout period between the last Q4W bevacizumab/ranibizumab injection and the first Q8W aflibercept injection

 

Some anatomical lesions of neovascular maculopathy at enrollment and at the end of the follow-up including the type of choroidal neovascularization(occult/minimally classic, predominantly classic), serous and/or hemorrhagic detachment of the neurosensory retina, and retinal hard exudates

 

Anatomical types of macular edema (diffuse/subretinal fluid/cystic changes within the neurosensory retina/mixed type) at presentation and at month 12

 

Proportion of the...

Notes

Acknowledgments/disclosure

All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest. No financial disclosures. Both authors (D.C and M.C) were involved in the design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review or approval of the manuscript.

The authors have full control over the primary data and they agree to allow Graefe’s Archive for Clinical and Experimental Ophthalmology to review their data if requested.

Compliance with ethical standards

Conflict of interest

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

References

  1. 1.
    Muftuoglu IK, Tsai FF, Gaber R, Alam M, Meshi A, Freeman WR (2017) High-frequency aflibercept injections in persistent neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 255:709–717CrossRefPubMedGoogle Scholar
  2. 2.
    Jaffe GJ, Kaiser PK, Thompson D et al (2016) Differential response to anti-VEGF regimens in age-related macular degeneration patients with early persistent retinal fluid. Ophthalmology 123:1856–1864CrossRefPubMedGoogle Scholar
  3. 3.
    Papadopoulos N, Martin J, Ruan Q, Rafique A (2012) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab and bevacizumab. Angiogenesis 15:171–185CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Gharbiya M, Cruciani F, Mariotti C, Grandinetti F, Marenco M, Cacace V (2015) Choroidal thickness changes after intravitreal antivascular endothelial growth factor therapy for age-related macular degeneration: ranibizumab versus aflibercept. J Ocul Pharmacol Ther 31:357–362CrossRefPubMedGoogle Scholar
  5. 5.
    Julien S, Biesemeier A, Taubitz T, Schraermeyer U (2014) Different effects on intravitreally injected ranibizumab and aflibercept on retinal and chorodial tissues of monkey eyes. Br J Ophthalmol 98:813–825CrossRefPubMedGoogle Scholar
  6. 6.
    Călugăru D, Călugăru M (2017) Long-term results of pro re nata regimen of aflibercept treatment in persistent neovascular age-related macular degeneration. Am J Ophthalmol 173:145–146CrossRefPubMedGoogle Scholar
  7. 7.
    Călugăru D, Călugăru M (2017) Comparison of time to retreatment and visual function between ranibizumab and aflibercept in age-related macular degeneration. Am J Ophthalmol 174:181–182CrossRefPubMedGoogle Scholar
  8. 8.
    Călugăru D, Călugăru M (2017) Long-term outcomes of aflibercept treatment for neovascular age-related macular degeneration in a clinical setting. Am J Ophthalmol 174:185–186CrossRefPubMedGoogle Scholar
  9. 9.
    Călugăru D, Călugăru M (2017) Aflibercept in persistent neovascular age-related macular degeneration: comparison of different treatment strategies in switching therapy. Eye 31:162CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  1. 1.Department of OphthalmologyUniversity of Medicine Cluj-Napoca/RomaniaCluj-NapocaRomania

Personalised recommendations